These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23742947)

  • 1. Impact of anticoagulation on coronary flow in patients with non-ST elevation acute coronary syndrome.
    Kang J; Cho YS; Song HY; Kim HJ; Oh IY; Yoon CH; Suh JW; Kim KI; Chung WY; Youn TJ; Chae IH; Choi DJ
    Clin Appl Thromb Hemost; 2015 Jan; 21(1):48-57. PubMed ID: 23742947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
    Thomas MP; Mahaffey KW; Chiswell K; Cohen M; Kontos MC; Antman EM; Ferguson JJ; Califf RM; Goodman SG; Becker RC
    J Thromb Thrombolysis; 2012 Jul; 34(1):114-9. PubMed ID: 22323092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.
    Lefebvre CW; Hoekstra J
    Hosp Pract (1995); 2010 Apr; 38(2):40-9. PubMed ID: 20469612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
    Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
    Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
    Wang TY; Chen AY; Peterson ED; Becker RC; Gibler WB; Ohman EM; Roe MT
    Eur Heart J; 2008 May; 29(9):1103-9. PubMed ID: 18353757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
    Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
    Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT;
    Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines.
    Eisen A; Giugliano RP
    Cardiol Rev; 2016; 24(4):170-6. PubMed ID: 26186386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithrombotic therapy of acute coronary syndromes].
    Hölschermann H
    Hamostaseologie; 2007 Dec; 27(5):319-25; quiz 326-7. PubMed ID: 18060240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.